EU insists that benefits of AstraZeneca vaccine outweigh the risks

EU insists that benefits of AstraZeneca vaccine outweigh the risks. The epidemic kills thousands of people every day.

According to the Associated Press report on the 16th, the European Union’s drug regulatory agency insisted on Tuesday that there was “no indication” that the AstraZeneca vaccine would cause blood clots. At the same time, governments around the world are facing the most severe dilemma: either continue to promote this life-saving vaccine, or suspend the use of this vaccine because of reports that some vaccinators have thrombosis problems.

The European Medicines Agency (EMA) also urges governments not to stop vaccination when the epidemic kills thousands of people every day. The agency’s executive director, Emer Cooke, said: “We still firmly believe that the benefits of the AstraZeneca vaccine in preventing new coronavirus pneumonia and the risks of hospitalization and death outweigh the risks of side effects.”

However, many countries hold different views on this, and have halted the vaccination of the vaccine, waiting for the EMA’s review results. Germany, Italy, France, Spain and other major countries have expressed that they will suspend vaccination plans. This Tuesday, Sweden is the latest country to do so, and it has also chosen to be cautious rather than vaccination speed.

Thailand was the first country outside Europe to suspend the use of AstraZeneca vaccine, but the Prime Minister of that country withdrew the decision after receiving a dose of the vaccine on Tuesday. Indonesia also stopped the use of this vaccine this week, saying that it will wait for the relevant report from the World Health Organization.

The Associated Press pointed out that AstraZeneca’s vaccine had previously encountered problems in data reporting. Some people have been concerned about the vaccine’s effectiveness among the elderly, which makes it difficult for the company to gain public trust. According to data compiled by the European Center for Disease Control and Prevention, more than half of the 15 million doses of AstraZeneca vaccine delivered to the 27 EU member states are still in stock.

According to reports, the latest controversy may further weaken European people’s confidence in vaccines. The person in charge of EMA pointed out that tens of thousands of people in the European Union suffer from blood clots for various reasons each year. In the clinical studies of the AstraZeneca vaccine, there is no report on the increase in the incidence of blood clots. Nevertheless, the experts will still conduct a “very rigorous analysis” and make recommendations on Thursday.

The Associated Press said that the current situation has left a few countries such as Belgium, Poland, Romania and Greece that still insist on the use of AstraZeneca vaccines increasingly isolated. However, experts point out that such worries are inevitable in mass vaccination campaigns.

(source:internet, reference only)

Disclaimer of medicaltrend.org